Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Innovative-Molecules

More Like This

PR Newswire associated0

Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir

Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program

PR Newswire associated0

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Business Wire logo

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

PR Newswire associated0

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results